CABLIVI pharmacy ordering information
Consider stocking or consigning CABLIVI so that therapy is on hand when it’s needed most. CABLIVI is available through a network of authorized specialty distributors (SD) for hospital acquisition. Hospitals and health systems can obtain CABLIVI by placing an order to stock or consign through 1 of the 3 authorized SDs below. It is up to your institution to determine the procurement option that works best for your practice or facility.
To help your patients transition from hospital to home, complete the CABLIVI Patient Enrollment Form as soon as treatment is initiated. Download, print, and fax the enrollment form to 800-914-0694 to ensure your patients have access to support.
Because prior authorization for outpatient use may take several days, it is recommended that healthcare providers initiate the process simultaneously with the start of inpatient treatment.
CABLIVI Patient Solutions:
Biologics, the specialty pharmacy provider for CABLIVI:
CABLIVI is contraindicated in patients with a previous severe hypersensitivity reaction to caplacizumab-yhdp or to any of its excipients. Hypersensitivity reactions have included urticaria.
The most common adverse reactions (>15% of patients) were epistaxis (29%), headache (21%) and gingival bleeding (16%).
Concomitant use of CABLIVI with any anticoagulant may increase the risk of bleeding. Assess and monitor closely for bleeding with concomitant use.
There are no available data on CABLIVI use in pregnant women to inform a drug associated risk of major birth defects and miscarriage.
CABLIVI (caplacizumab-yhdp) is indicated for the treatment of adult patients with acquired thrombotic thrombocytopenic purpura (aTTP), in combination with plasma exchange and immunosuppressive therapy.